Literature DB >> 36267710

FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases.

Carlotta Antoniotti1,2, Guglielmo Vetere1,2, Chiara Cremolini1,2.   

Abstract

Entities:  

Year:  2022        PMID： 36267710      PMCID： PMC9577793          DOI： 10.21037/atm-22-3656

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  22 in total

1.  Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.

Authors:  David Cunningham; Istvan Lang; Eugenio Marcuello; Vito Lorusso; Janja Ocvirk; Dong Bok Shin; Derek Jonker; Stuart Osborne; Niko Andre; Daniel Waterkamp; Mark P Saunders
Journal:  Lancet Oncol       Date:  2013-09-10       Impact factor: 41.316

2.  Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.

Authors:  Chiara Cremolini; Carlotta Antoniotti; Daniele Rossini; Sara Lonardi; Fotios Loupakis; Filippo Pietrantonio; Roberto Bordonaro; Tiziana Pia Latiano; Emiliano Tamburini; Daniele Santini; Alessandro Passardi; Federica Marmorino; Roberta Grande; Giuseppe Aprile; Alberto Zaniboni; Sabina Murgioni; Cristina Granetto; Angela Buonadonna; Roberto Moretto; Salvatore Corallo; Stefano Cordio; Lorenzo Antonuzzo; Gianluca Tomasello; Gianluca Masi; Monica Ronzoni; Samantha Di Donato; Chiara Carlomagno; Matteo Clavarezza; Giuliana Ritorto; Andrea Mambrini; Mario Roselli; Samanta Cupini; Serafina Mammoliti; Elisabetta Fenocchio; Enrichetta Corgna; Vittorina Zagonel; Gabriella Fontanini; Clara Ugolini; Luca Boni; Alfredo Falcone
Journal:  Lancet Oncol       Date:  2020-03-09       Impact factor: 41.316

3.  Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.

Authors:  Chiara Cremolini; Mariaelena Casagrande; Fotios Loupakis; Giuseppe Aprile; Francesca Bergamo; Gianluca Masi; Roberto Moretto R; Filippo Pietrantonio; Federica Marmorino; Gemma Zucchelli; Gianluca Tomasello; Giuseppe Tonini; Giacomo Allegrini; Cristina Granetto; Laura Ferrari; Lucio Urbani; Umberto Cillo; Pierluigi Pilati; Elisa Sensi; Alessio Pellegrinelli; Massimo Milione; Gabriella Fontanini; Alfredo Falcone
Journal:  Eur J Cancer       Date:  2016-12-13       Impact factor: 9.162

4.  The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.

Authors:  Julian Walter Holch; Ingrid Ricard; Sebastian Stintzing; Dominik Paul Modest; Volker Heinemann
Journal:  Eur J Cancer       Date:  2016-11-29       Impact factor: 9.162

5.  FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

Authors:  Chiara Cremolini; Fotios Loupakis; Carlotta Antoniotti; Cristiana Lupi; Elisa Sensi; Sara Lonardi; Silvia Mezi; Gianluca Tomasello; Monica Ronzoni; Alberto Zaniboni; Giuseppe Tonini; Chiara Carlomagno; Giacomo Allegrini; Silvana Chiara; Mauro D'Amico; Cristina Granetto; Marina Cazzaniga; Luca Boni; Gabriella Fontanini; Alfredo Falcone
Journal:  Lancet Oncol       Date:  2015-08-31       Impact factor: 41.316

Review 6.  Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus.

Authors:  René Adam; Aimery de Gramont; Joan Figueras; Norihiro Kokudo; Francis Kunstlinger; Evelyne Loyer; Graeme Poston; Philippe Rougier; Laura Rubbia-Brandt; Alberto Sobrero; Catherine Teh; Sabine Tejpar; Eric Van Cutsem; Jean-Nicolas Vauthey; Lars Påhlman
Journal:  Cancer Treat Rev       Date:  2015-06-30       Impact factor: 12.111

7.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Authors:  E Van Cutsem; A Cervantes; R Adam; A Sobrero; J H Van Krieken; D Aderka; E Aranda Aguilar; A Bardelli; A Benson; G Bodoky; F Ciardiello; A D'Hoore; E Diaz-Rubio; J-Y Douillard; M Ducreux; A Falcone; A Grothey; T Gruenberger; K Haustermans; V Heinemann; P Hoff; C-H Köhne; R Labianca; P Laurent-Puig; B Ma; T Maughan; K Muro; N Normanno; P Österlund; W J G Oyen; D Papamichael; G Pentheroudakis; P Pfeiffer; T J Price; C Punt; J Ricke; A Roth; R Salazar; W Scheithauer; H J Schmoll; J Tabernero; J Taïeb; S Tejpar; H Wasan; T Yoshino; A Zaanan; D Arnold
Journal:  Ann Oncol       Date:  2016-07-05       Impact factor: 32.976

8.  Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.

Authors:  T Gruenberger; J Bridgewater; I Chau; P García Alfonso; M Rivoire; S Mudan; S Lasserre; F Hermann; D Waterkamp; R Adam
Journal:  Ann Oncol       Date:  2014-12-23       Impact factor: 32.976

9.  mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial.

Authors:  Cailu Shen; Huabin Hu; Yue Cai; Jiayu Ling; Jianwei Zhang; Zehua Wu; Xiaoyu Xie; Meijin Huang; Hui Wang; Liang Kang; Ping Lan; Xiaojian Wu; Guangjian Liu; Yunle Wan; Zhiyang Zhou; Yan Huang; Fangqian Li; Huaiming Wang; Tenghui Ma; Shuangling Luo; Yonghua Cai; Lishuo Shi; Yanhong Deng
Journal:  Ann Transl Med       Date:  2022-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.